Ligand Pharmaceuticals Completes Dividend Distribution
Ligand Pharmaceuticals Announces $353 Million Cash Dividend and Share Repurchase Authorization
Ligand Pharmaceuticals Announces Fourth Quarter Results
Ligand Announces Changes and Additions to the Board of Directors
Ligand Pharmaceuticals Completes Sale of AVINZA to King Pharmaceuticals
Ligand Announces Results of Special Stockholder Meeting
Ligand Announces Corporate Restructuring
Ligand Sets February 12, 2007 as Date for Special Meeting of Stockholders
Ligand Appoints John L. Higgins Chief Executive Officer
